New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:31 EDTFRXForest Labs completes $2.9B acquisition of Aptalis
Forest Laboratories announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis. The companies will begin combined operations today, with Aptalis operating as a subsidiary of Forest Laboratories. The acquisition of Aptalis strengthens Forestís gastrointestinal franchise in the U.S. and Canada, complements its growing cystic fibrosis business in Europe, and creates a cystic fibrosis business in the U.S. market. Forest expects the acquisition to add approximately $700M in revenue and about 78c per share to the companyís non-GAAP EPS in FY15. The acquisition also adds assets to Forestís pipeline in both therapeutic areas. Post-acquisition integration activities will begin today. As previously announced, Forest anticipates $125M in cost synergies by FY16.
News For FRX From The Last 14 Days
Check below for free stories on FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for FRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use